Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Rumor Mill: Indian drug makers court Par
At least three Indian drug makers were spotted with chocolate and flowers at the headquarters of Par Pharmaceuticals, one of the top 10 generics companies in the U.S. Several Indian newspapers are reporting today that Ranbaxy Laboratories, Wockhardt, and Sun Pharma are all three courting the company. The three would-be suitors declined comment.
Curiously, Ranbaxy has already been in the gossip columns about a purported offer for Bradley Pharmaceuticals, which took non-binding bids several weeks ago. And Sun Pharma has agreed to pay $454 million for Taro Pharmaceutical, an Israeli-based generics maker. Is Par Pharma--with a market cap of $692 million--a back-up plan? Well, as they say, all's fair in love and business.
- read this report from India's Economic Times
Related Articles:
Par to restate earnings. Report
Rumor Mill: Dr. Reddy bids for Bradley. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


